EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

Phaedra C Ghazi iD, Kayla T O'Toole, Sanjana Srinivas Boggaram, Michael T Scherzer, Mark R Silvis, Yun Zhang, Madhumita Bogdan, Bryan D Smith, Guillermina Lozano iD, Daniel L Flynn, Eric L Snyder iD, Conan G Kinsey iD und 1 weitere

eLife · 2024

DOI: 10.7554/elife.96992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Phaedra C Ghazi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncological Sciences, University of Utah, Salt Lake City, United States. Hauptthemen laut MEDLINE: Autophagy-Related Protein-1 Homolog, Cell Proliferation, Intracellular Signaling Peptides and Proteins, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutational activation of KRAS occurs commonly in lung carcinogenesis and, with the recent U.S. Food and Drug Administration approval of covalent inhibitors of KRAS G12C such as sotorasib or adagrasib, KRAS oncoproteins are important pharmacological targets in non-small cell lung cancer (NSCLC). However, not all KRAS G12C -driven NSCLCs respond to these inhibitors, and the emergence of drug resistance in those patients who do respond can be rapid and pleiotropic. Hence, based on a backbone of covalent inhibition of KRAS G12C , efforts are underway to develop effective combination therapies. Here, we report that the inhibition of KRAS G12C signaling increases autophagy in KRAS G12C -expressing lung cancer cells. Moreover, the combination of DCC-3116, a selective ULK1/2 inhibitor, plus sotorasib displays cooperative/synergistic suppression of human KRAS G12C -driven lung cancer cell proliferation in vitro and superior tumor control in vivo. Additionally, in genetically engineered mouse models of KRAS G12C -driven NSCLC, inhibition of either KRAS G12C or ULK1/2 decreases tumor burden and increases mouse survival. Consequently, these data suggest that ULK1/2-mediated autophagy is a pharmacologically actionable cytoprotective stress response to inhibition of KRAS G12C in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autophagy-Related Protein-1 HomologCell ProliferationIntracellular Signaling Peptides and ProteinsLung NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsFemaleHumansMaleMiceAntineoplastic AgentsAutophagyCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalPiperazinesProtein Serine-Threonine KinasesPyridinesPyrimidines

Stichwörter der Autor:innen

KRASLKB1TP53ULKautophagycancer biologylung cancermouse

Substanzen

Antineoplastic AgentsAutophagy-Related Protein-1 HomologIntracellular Signaling Peptides and ProteinsKRAS protein, humanPiperazinesProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasib

Autor:innen und Institutionen

  • Department of Oncological Sciences, University of Utah, Salt Lake City, United States.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, United States.
  • Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, United States.
  • Deciphera Pharmaceuticals, St. Lawrence, United States.
  • Department of Pathology, University of Utah, Salt Lake City, United States.
  • Department of Internal Medicine, Division of Medical Oncology, University of Utah, Salt Lake City, United States.

ORCID-Profile: Phaedra C Ghazi, Guillermina Lozano, Eric L Snyder, Conan G Kinsey, Martin McMahon

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • National Cancer Institute
  • Huntsman Cancer Foundation
  • Huntsman Cancer Institute, University of Utah
  • V Foundation for Cancer Research

Zitieren

APA

Ghazi, P. C., O'Toole, K. T., Srinivas Boggaram, S., Scherzer, M. T., Silvis, M. R., Zhang, Y., Bogdan, M., Smith, B. D., Lozano, G., Flynn, D. L., Snyder, E. L., Kinsey, C. G., & McMahon, M. (2024). Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. https://doi.org/10.7554/elife.96992

Vancouver

Ghazi PC, O'Toole KT, Srinivas Boggaram S, Scherzer MT, Silvis MR, Zhang Y, et al. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife. 2024. doi:10.7554/elife.96992

BibTeX
@article{Ghazi2024,
  author = {Ghazi, Phaedra C and O'Toole, Kayla T and Srinivas Boggaram, Sanjana and Scherzer, Michael T and Silvis, Mark R and Zhang, Yun and Bogdan, Madhumita and Smith, Bryan D and Lozano, Guillermina and Flynn, Daniel L and Snyder, Eric L and Kinsey, Conan G and McMahon, Martin},
  title = {Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.96992}
}
Kostenlos starten →